SuperworthImmunocore price to book ratio IMCR
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 3.8×
- 3-year median
- 4.3×
- Against its 3-year history
- 11th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 3.6× to 9.1×
- Peer median
- 5.4×
Immunocore's price to book ratio is 3.8× as of Oct 23, 2026.
That is below its 3-year median of 4.3×, lower than on 89% of days in the last 3 years.
Over that time it ranged from 3.6× in Oct 2026 to 9.1× in Mar 2024.
The median for 9 biotech stocks of a similar size is 5.4×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.8× | 3.6× | 4.5× |
| 2025 | 4.6× | 3.7× | 5.0× |
| 2024 | 3.9× | 3.8× | 9.1× |
Against its peers
Companies in Biotechnology nearest Immunocore's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| IMCRImmunocore | 3.8× |
| VCELVericel | 5.9× |
| ADMAAdma Biologics | 5.9× |
| MGTXMeiraGTx | 4.1× |
| KRYSKrystal Biotech | 6.8× |
| RGENRepligen | 4.7× |
| TECHBIO-TECHNE | 5.4× |
| PLXProtalix BioTherapeutics | 2.9× |
| HALOHalozyme Therapeutics | 99.3× |
| NBIXNeurocrine Biosciences | 3.9× |
| Peer median | 5.4× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Immunocore
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.